Evidence map›Paper›PMID 40831927›Full record

ArticleFrontiers in oncology2025

Evolutionary dynamics of recurrent hepatocellular carcinoma under divergent immune selection pressures.

Ankur Chakravarthy, Elisa Pasini, Xun Zhao, Jeffrey To, Shu Yi Roxana Shen, Sandra Fischer, Anand Ghanekar, Arndt Vogel, Robert C Grant, Jennifer Knox and 4 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ankur ChakravarthyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Elisa PasiniAjmera Transplant Centre, University Health Network, Toronto, ON, Canada.
Xun ZhaoAjmera Transplant Centre, University Health Network, Toronto, ON, Canada.
Jeffrey ToAjmera Transplant Centre, University Health Network, Toronto, ON, Canada.
Shu Yi Roxana ShenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Sandra FischerDepartment of Pathology, University Health Network, Toronto, ON, Canada.
Anand GhanekarDivision of Multi-Organ Transplant and Hepato-Pancreato-Biliary (HPB) Surgical Oncology, Department of General Surgery, University Health Network, Toronto, ON, Canada.
Arndt VogelPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Robert C GrantPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jennifer KnoxPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Gonzalo SapisochinDivision of Multi-Organ Transplant and Hepato-Pancreato-Biliary (HPB) Surgical Oncology, Department of General Surgery, University Health Network, Toronto, ON, Canada.
Gregory J GoresDivision of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, United States.
Daniel De CarvalhoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Mamatha BhatAjmera Transplant Centre, University Health Network, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal, aggressive malignancy. Little is known about the evolutionary trajectories of HCC and how clinical decision-making could be informed based on biopsies of the initial tumour. Here, we report the whole-exome sequencing of a unique series of resected HCC tumours and matched recurrences. This cohort included patients who received a liver transplant and who were immunosuppressed at time of recurrence, in comparison to patients who underwent liver resection for HCC and immunocompetent at time of recurrence, therefore facilitating analyses of immune selection in driving evolutionary divergence. We find extensive evolutionary divergence between baseline and recurrent tumours, with the majority of mutations in our cohort being private, in the process informing sampling guidelines for precision oncology in this disease. We also find no evidence that immunosuppression relaxes immune selection pressures, given the absence of a genomic footprint reflecting the presentation of neoantigens or altered dynamics of genomic evolution. We attribute this to the presence of genetic lesions that confer the capabilities of immune evasion in these tumours prior to transplantation, and then validate the link between immune selection pressures and the emergence of these lesions in publicly available HCC datasets. Our findings point to HCC as a cancer with extensive evolutionary divergence over time, partly defined by an irreversible, genetically determined trajectory towards immune escape.

Indexed as

hepatocellular carcinomaimmune evasionimmune selectiontumour evolutionwhole-exome sequencing

Identifiers

PMID40831927
PMCPMC12359061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.